The Role of JAK Inhibitors in the Management of Myelofibrosis

Allogeneic hematopoietic cell transplant is the only potentially curative treatment option resulting in long-term remissions for patients with myelofibrosis (MF), but it is associated with a significant rate of transplant-related complications and morbidity in patients with lower-risk MF.

NCCN Guidelines® Insights - Systemic Mastocytosis, Version 3.2024
The NCCN Guidelines for Systemic Mastocytosis provide evidence- and consensus-based recommendations for the diagnosis and comprehensive care of patients with systemic mastocytosis. The multidisciplinary panel of experts convenes at least once a year to review requested changes to the guidelines from both internal and external entities as well as to discuss data on existing and new therapies. These NCCN Guidelines Insights focus on some of the recent updates to the guidelines.
Updates in the Management of Myelofibrosis
As data on novel therapies emerge, it is essential that clinicians are aware of recent developments so they can best evaluate the needs of the patients and select an optimal therapeutic strategy with the goal of improving clinical outcomes.
Chronic Myeloid Leukemia/Myelofibrosis: TKI Therapy and Toxicity Management
There is a continuing need to educate clinicians about the differences in toxicity profiles between TKIs and the various strategies that are being evaluated in clinical trials to mitigate the risk of adverse events associated with TKI therapy for CML and MPN.
Management of Polycythemia Vera and Essential Thrombocythemia
It is important for physicians to stay up to date on treatment recommendations so they can best evaluate available data and select the optimal therapeutic strategy based on the patient’s clinical needs. 
Mutational Landscape in Myeloproliferative Neoplasms: Implications on Prognosis and Clinical Management
The diagnosis and management of patients with myeloproliferative neoplasms (MPN) has evolved since the identification of “driver” mutations, namely JAK2, CALR, and MPL mutations. Health care providers are challenged to stay abreast of new developments in the field that may help inform clinical decision-making.
Interactive Online Case Studies: Leukemia, Myelodysplastic Syndromes, and Myeloproliferative Disorders - Case 3
Myeloproliferative Neoplasms: Emerging Treatment Options for Myelofibrosis
Appropriate symptom assessment is essential to develop an effective symptom-directed approach. Informing clinicians about the recent advances can help them develop an optimal treatment strategy with the incorporation of novel agents into the treatment plan based on the patient’s clinical needs.
Prognostic Significance of Mutations in Myeloproliferative Neoplasms

The diagnosis and management of patients with myeloproliferative neoplasms (MPN) has evolved since the identification of “driver” mutations (JAK2, CALR, and MPL mutations).

Patient Case Studies and Panel Discussion: Leukemia and Myeloproliferative Neoplasms

Although advances in treatment options for patients with hematologic malignancies are encouraging, the rapidly changing scientific and clinical environment represents a daunting challenge for practitioners.

Pages

Subscribe to RSS - Myeloproliferative Neoplasms